Continence and Pelvic Health Assessment Instruments

Instruments here separate cleanly into severity and impact. Severity measures such as the Incontinence Severity Index, the Wexner Faecal Incontinence Score, the International Prostate Symptom Score and the American Urological Association Symptom Index quantify how often and how much. Impact measures such as the Incontinence Impact Questionnaire, the Pelvic Floor Impact Questionnaire and the Faecal Incontinence Quality of Life Scale quantify what it does to the person's life. The Pelvic Organ Prolapse Quantification System is different again: it is an anatomical staging system recorded by examination, not a patient-reported measure.

The Female Sexual Function Index sits here because pelvic floor dysfunction, prolapse and their treatments affect sexual function directly, and studies in this area that omit it miss an outcome patients rate highly.

Severity and impact correlate weakly, and that is the central practical point in this group. Two people with the same number of leakage episodes can report entirely different levels of restriction depending on their circumstances, occupation and access to facilities. A treatment that reduces episode frequency without changing what the person feels able to do has not delivered what most patients came for, and a study measuring only severity will not detect that.

Anatomical staging behaves differently again. Prolapse stage correlates poorly with symptoms, and treating an anatomical result as the outcome overstates benefit. Where an anatomical measure is the primary endpoint, a patient-reported measure should sit alongside it.

Check whether the instrument was validated in the sex and population being studied. Several continence instruments were developed in women and are used in men without separate validation, and prostate symptom scores obviously do not transfer the other way.

Check the recall period, which varies widely here and materially changes reported severity.

Plan for the sensitivity of the subject matter. Completion rates on continence and sexual function questionnaires are lower than average, and the drop-out is not random: people with more severe symptoms are more likely to skip items. A private, self-completed digital format usually improves completeness compared with an interview, and the mode should be fixed and recorded because it changes the answers.

Why measure both severity and impact?

Because they correlate weakly. Episode frequency does not predict how restricted a person feels, and treatments can move one without the other. Most studies in this area need both to describe an outcome patients would recognise.

Does prolapse stage predict symptoms?

Poorly. Anatomical staging and symptom burden correlate weakly, so an anatomical result on its own is not evidence of patient benefit. Pair it with a patient-reported impact measure.

Are continence instruments validated for both men and women?

Not all of them. Several were developed in women, and prostate symptom scores apply only to men. Check the validation population before applying an instrument to a mixed cohort.

How do I improve completion rates on these questionnaires?

Use a private self-completed format rather than an interview, explain why the questions are being asked, and allow completion outside a clinic setting. Record the mode used, because it affects the answers and cannot be changed mid-study.